New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
12:48 EDTKPTI, IPCI, TWTR, FB, TSLA, NFLX, TXMD, GES, ABBV, SHPGOn The Fly: Midday Wrap
Stocks on Wall Street were lower for a second straight session at midday, with a number of tech "momentum stocks" among the hardest hit names. Slides in prominent high-fliers like Netflix (NFLX), Tesla (TSLA), Facebook (FB) and Twitter (TWTR) weighed on the Nasdaq, pushing the tech-heavy index to a nearly 2% decline near noon. The Dow and S&P were lower as well as the slide has been broad-based, with investors express showing caution ahead of the start of the earnings season. ECONOMIC EVENTS: In the U.S., the Job Openings and Labor Turnover Survey, or JOLTs report, showed a 171K increase in job openings to 4.635M, marking a fourth straight monthly gain. A report on consumer credit growth in May is due out at 3:00 pm ET. COMPANY NEWS: AbbVie (ABBV) made a fourth offer to buy Shire (SHPG), raising the price of its bid by 11% to over $51B in cash and stock. For its part, Shire responded by saying that AbbVie did not make the revised proposal to Shire before the announcement and that its board will meet to consider the revised offer. Near noon, Shire shares trading in New York fell 2.7%, while AbbVie slipped 3.2%. MAJOR MOVERS: Among the notable gainers was TherapeuticsMD (TXMD), which jumped 14% to trade near $4.72 after FBR Capital initiated the stock with an Outperform rating and $34 price target. Also higher was apparel designer and retailer Guess (GES), which climbed 5% after research firm Piper Jaffray upgraded the stock to Overweight from Neutral in a note to investors earlier today. Among the noteworthy losers was Karyopharm (KPTI), which slipped 11% after Oppenheimer assumed coverage of its stock with a Perform rating, down from its prior rating of Outperform. Also lower following its quarterly report was Intellipharmaceutics (IPCI), which fell 11% after reporting a net loss for its second fiscal quarter. INDEXES: Near midday, the Dow was down 140.51, or 0.83%, to 16,883.70, the Nasdaq was down 71.67, or 1.61%, to 4,379.86, and the S&P 500 was down 16.85, or 0.85%, to 1,960.80.
News For SHPG;ABBV;GES;TXMD;NFLX;TSLA;FB;TWTR;IPCI;KPTI From The Last 14 Days
Check below for free stories on SHPG;ABBV;GES;TXMD;NFLX;TSLA;FB;TWTR;IPCI;KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 11, 2014
06:02 EDTFBFacebook implied volatility of 26 at lower end of index mean range
Subscribe for More Information
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
18:33 EDTTWTROn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTTWTRTwitter to offer $1.3B in convertible notes
Subscribe for More Information
16:00 EDTTSLA, NFLX, TWTROptions Update; September 10, 2014
Subscribe for More Information
13:26 EDTTSLATesla gigafactory payroll seen at $370M by 2018, MarketWatch reports
Tesla's gigafactory is estimated to create 6,500 direct jobs, 16,200 indirect jobs, and as much as $370M a year in payroll by 2018, MarketWatch reports, citing a study commissioned by the Nevada governor's office. Reference Link
12:04 EDTFBFacebook testing tool that lets users schedule post deletions, The Next Web says
Facebook is testing a tool that will allow users to create self-destructing Facebook posts that disappear after a specified period of time, The Next Web reports. A spokesperson has confirmed, saying "We’re running a small pilot of a feature on Facebook for iOS that lets people schedule deletion of their posts in advance." Reference Link
12:04 EDTTWTRTwitter volatility low as shares trend higher
Subscribe for More Information
10:27 EDTTWTRTwitter moves higher following upgrade, levels to watch
Subscribe for More Information
10:26 EDTNFLXDiscovery CEO says likes doing deals with Netflix, Amazon
CEO David Zaslav says Comcast (CMCSA)/Time Warner Cable (TWC) deal "presents some serious issues," is talking to FCC about deal. Says will be opportunistic with international acquisitions, but "We don't feel like we need to acquire anything at this point." Says has more subscribers than ESPN with Europsport. Comments made at the Goldman Sachs Communacopia Conference.
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTTWTROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: African Barrick Gold (ABGLY) upgraded to Neutral from Sell at Goldman... ArcelorMittal (MT) upgraded to Overweight from Underweight at Barclays... CRH Plc. (CRH) upgraded to Outperform from Underperform at Raymond James... Callon Petroleum (CPE) upgraded to Buy from Neutral at SunTrust... Coach (COH) upgraded to Overweight from Neutral at Atlantic Equities... Hartford Financial (HIG) upgraded to Outperform from Market Perform at FBR Capital... Huntsman (HUN) upgraded to Buy from Neutral at Citigroup... Imperva (IMPV) upgraded to Outperform from Perform at Oppenheimer... L Brands (LB) upgraded at Credit Suisse... Marcus (MCS) upgraded to Buy from Neutral at B. Riley... Noodles & Company (NDLS) upgraded to Buy from Neutral at UBS... Sunoco Logistics (SXL) upgraded to Overweight from Equal Weight at Barclays... Triangle Petroleum (TPLM) upgraded to Buy from Accumulate at KLR Group... Twitter (TWTR) upgraded to Buy from Neutral at UBS.
09:38 EDTNFLX, TSLA, TWTRActive equity options trading on open
Subscribe for More Information
09:22 EDTTWTROn The Fly: Pre-market Movers
HIGHER: Twitter (TWTR), up 2.8% after upgraded at UBS... SunEdison (SUNE), up 2.7% after Google (GOOG) to provide $145M investment in the company's Regulus solar plant... Camtek (CAMT), up 15% after receiving new orders of $3.0M from large OSAT... Doral Financial (DRL), up 12.5% after announcing sale of approximately $430M in assets... Imperva (IMPV), up 1.5% after upgraded at Oppenheimer... Mandalay Digital (MNDL), up 13.7% after updating its guidance. UP AFTER EARNINGS: Land's End (LE), up 8.7%... Palo Alto (PANW), up 4.4%. LOWER: eBay (eBAY), down 2.6% after downgraded at Piper Jaffray following yesterday's launch of Apple Pay (AAPL)... Mobileye (MBLY), down 2.5% after downgraded at Deutsche Bank... Krispy Kreme (KKD), down 2% after Q2 earnings report... GT Advanced (GTAT), down 7% after downgraded at Goldman and Piper Jaffray... Boyd Gaming (BYD), down 3.3% after downgraded at Morgan Stanley... Urban Outfitters (URBN), down 2% after reporting Q3 SSS were so far in the low single-digits negative... Armada Hoffler (AHH), down 6% after filing to sell 5M shares of common stock... AvalonBay (AVB), down 1.8% after to sell 4.5M shares in a forward sales agreement with Goldman... AngloGold (AU), down 12% after announcing plans to restructure its international mining under a new company and saying equity capital raising being contemplated.
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
06:26 EDTNFLXNetflix initiated with a Neutral at SunTrust
Subscribe for More Information
06:04 EDTNFLXNetflix initiated with a Buy at Canaccord
Target $550.
05:53 EDTTWTRTwitter upgraded to Buy from Neutral at UBS
UBS upgraded its rating on Twitter (TWTR) shares to Buy from Neutral after its advertising channel checks indicated the company is seeing positive momentum with objective-based campaigns. UBS analyst Eric Sheridan believes Twitter is positioned strongly within the digital advertising space and he raised his price target for shares to $65 from $50. The stock closed yesterday down $1.39 to $50.61.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use